Own immune cells delivered to liver to fight melanoma

NCT ID NCT04812470

Completed Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tested whether it is safe and feasible to give patients their own immune cells (called tumor infiltrating lymphocytes, or TIL) directly into the liver artery. Eight adults with melanoma that had spread to the liver received the TIL infusion along with chemotherapy and an immune booster. The main goal was to check for side effects and see if the approach is practical.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous tumor infiltrating lymphocytes (TIL) plus melphalan and interleukin-2
What this could lead to: If it works, this could point toward a new way to treat melanoma that has spread to the liver using the patient's own immune cells.
What could go wrong: This is a very early phase 1 trial with only 8 people, so it is too small to prove effectiveness. The treatment involves strong chemotherapy and immune stimulation, which can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CUTANEOUS MELANOMA METASTATIC UVEAL MELANOMA

Contacts and locations

Locations

Department of Oncology, Sahlgrenska University Hospital

Gothenburg, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.